DK0773785T3 - Behandling af cancer ced hjælp af HSV-mutant - Google Patents

Behandling af cancer ced hjælp af HSV-mutant

Info

Publication number
DK0773785T3
DK0773785T3 DK95927034T DK95927034T DK0773785T3 DK 0773785 T3 DK0773785 T3 DK 0773785T3 DK 95927034 T DK95927034 T DK 95927034T DK 95927034 T DK95927034 T DK 95927034T DK 0773785 T3 DK0773785 T3 DK 0773785T3
Authority
DK
Denmark
Prior art keywords
cancer
mutant
ced
treatment
hsv mutant
Prior art date
Application number
DK95927034T
Other languages
English (en)
Inventor
Alasdair Roderick Maclean
Susanne Moira Brown
Nigel William Fraser
Bruce Paul Randazzo
Original Assignee
Univ Glasgow
Wistar Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10759079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0773785(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Glasgow, Wistar Inst filed Critical Univ Glasgow
Application granted granted Critical
Publication of DK0773785T3 publication Critical patent/DK0773785T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DK95927034T 1994-07-29 1995-07-28 Behandling af cancer ced hjælp af HSV-mutant DK0773785T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9415320A GB9415320D0 (en) 1994-07-29 1994-07-29 Cancer treatment
PCT/GB1995/001791 WO1996003997A2 (en) 1994-07-29 1995-07-28 Treatment of cancer using hsv mutant

Publications (1)

Publication Number Publication Date
DK0773785T3 true DK0773785T3 (da) 2002-10-07

Family

ID=10759079

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95927034T DK0773785T3 (da) 1994-07-29 1995-07-28 Behandling af cancer ced hjælp af HSV-mutant

Country Status (12)

Country Link
US (3) US7674468B2 (da)
EP (2) EP1192948A3 (da)
JP (2) JP4321723B2 (da)
AT (1) ATE219681T1 (da)
AU (1) AU3119995A (da)
CA (1) CA2196315C (da)
DE (1) DE69527204T2 (da)
DK (1) DK0773785T3 (da)
ES (1) ES2179880T3 (da)
GB (1) GB9415320D0 (da)
PT (1) PT773785E (da)
WO (1) WO1996003997A2 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9415320D0 (en) * 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
ZA966287B (en) * 1995-07-27 1998-03-09 American Cyanamid Co Avirulent herpetic viruses useful as tumoricidal agents and vaccines.
EP1314430A1 (en) * 1996-01-25 2003-05-28 The University Court Of The University Of Glasgow Treatment of non-neuronal cancer using HSV mutant
US5824318A (en) * 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
GB9615794D0 (en) 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
CN1477964A (zh) 1999-04-15 2004-02-25 应用病毒治疗肿瘤
US6897057B1 (en) 1999-08-31 2005-05-24 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
CA2383372C (en) * 1999-08-31 2010-04-13 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression
AU782402B2 (en) 1999-09-17 2005-07-28 Wellstat Biologics Corporation Oncolytic virus
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
EP1381280B1 (en) 2001-03-27 2011-05-11 Catherex, Inc. Viral vectors and their use in therapeutic methods
GB0203285D0 (en) 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
JP2004099584A (ja) 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
WO2004078206A1 (en) 2003-03-07 2004-09-16 Robarts Research Institute Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
ATE539162T1 (de) 2003-03-27 2012-01-15 Ottawa Hospital Res Inst Mutierte viren der vesikulären stomatitis und deren verwendung
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
JP2007511216A (ja) 2003-11-17 2007-05-10 クルセイド ラボラトリーズ リミテッド 変異ウイルス
DK2388315T3 (da) 2005-03-07 2014-08-25 Univ Western Ontario Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling
WO2009016433A2 (en) 2006-09-15 2009-02-05 Ottawa Health Research Institute Oncolytic rhabdovirus
KR102323872B1 (ko) * 2016-04-22 2021-11-08 임비라 컴퍼니 리미티드 암치료용 종양 용해성 단순 헤르페스 바이러스(oHSV) 절대 벡터 및 그 구조체의 구조
KR102920599B1 (ko) * 2020-09-04 2026-01-29 이노웨이스톤 테라퓨틱스 리미티드 항종양 활성을 갖는 화합물 및 이의 용도

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859587A (en) * 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
US5328688A (en) * 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
CA2051289C (en) * 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells
GB9102126D0 (en) * 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
CA2132976C (en) * 1992-03-31 2003-12-30 Bernard Roizman Methods and compositions for gene, tumor, and viral infection therapy, and prevention of programmed cell death (apoptosis)
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US6139834A (en) * 1994-06-23 2000-10-31 Georgetown University Replication-competent Herpes simplex virus mediates destruction of neplastic cells
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
EP0862445B2 (en) 1995-10-06 2017-03-22 Arch Development Corporation Combination of herpes simplex virus and chemotherapy for treating cancer
EP1314430A1 (en) * 1996-01-25 2003-05-28 The University Court Of The University Of Glasgow Treatment of non-neuronal cancer using HSV mutant
GB0203285D0 (en) 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
JP2007511216A (ja) 2003-11-17 2007-05-10 クルセイド ラボラトリーズ リミテッド 変異ウイルス
WO2007026146A1 (en) 2005-08-30 2007-03-08 Crusade Laboratories Limited Treatment using herpes simplex virus
GB0326798D0 (en) 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
WO2007132169A1 (en) 2006-05-11 2007-11-22 Crusade Laboratories Limited Mutant hsv, materials and methods for generation of mutant hsv
JP5442452B2 (ja) 2007-02-16 2014-03-12 ウイルツ・バイオロジクス・リミテッド 単純ヘルペスウイルスおよびウイルス複製法
GB0714578D0 (en) 2007-07-26 2007-09-05 Crusade Lab Ltd Viruses

Also Published As

Publication number Publication date
JP4321723B2 (ja) 2009-08-26
US20120141418A1 (en) 2012-06-07
ATE219681T1 (de) 2002-07-15
WO1996003997A2 (en) 1996-02-15
WO1996003997A3 (en) 1996-05-02
EP0773785A2 (en) 1997-05-21
JP2008037869A (ja) 2008-02-21
EP0773785B1 (en) 2002-06-26
US8067012B2 (en) 2011-11-29
US7674468B2 (en) 2010-03-09
PT773785E (pt) 2002-11-29
AU3119995A (en) 1996-03-04
JPH10503766A (ja) 1998-04-07
US20050260169A1 (en) 2005-11-24
EP1192948A2 (en) 2002-04-03
EP1192948A3 (en) 2002-09-04
CA2196315A1 (en) 1996-02-15
US20100172872A1 (en) 2010-07-08
DE69527204T2 (de) 2003-02-20
GB9415320D0 (en) 1994-09-21
DE69527204D1 (de) 2002-08-01
ES2179880T3 (es) 2003-02-01
CA2196315C (en) 2010-02-09

Similar Documents

Publication Publication Date Title
PT773785E (pt) Tratamento do cancro utilizando um mutante de hsv
AU676349B2 (en) Nucleic acid-binding oligomers possessing N-branching for therapy and diagnostics
ATE342724T1 (de) Verwendung von herpes-vektoren zur tumortherapie
ATE145126T1 (de) Intraokularlinsenset
DE69106603D1 (de) Fluorhaltiges Copolymer und dieses enthaltende härtbare Zusammensetzung.
IT8319483A0 (it) Dispositivo sensibile al tocco in particolare per l'impiego con una sorgente di luce sincronizzata come ad esempio un tubo a raggi catodici e/o simile.
EP1245208A3 (en) Face shield and face shield support assembly
DK0555370T3 (da) Metoder og anvendelser for effektive, genetiske suppressorelementer
FI952961A0 (fi) Dolostatiinianalogeja
ATE141946T1 (de) Hiv-2-virusvarianten
TR199701545T1 (xx) Yeni dolastatin t�revleri,haz�rlanmalar� ve kullan�mlar�
AU1550797A (en) Treatment of non-neuronal cancer using hsv mutant
NO953843D0 (no) Projeksjonsbildekilde med stor lysstyrke
ES2056395T3 (es) Marco para carteles.
DE59803648D1 (de) Faltbare intraokularlinse
AU7161994A (en) nucleic acid-binding oligomers possessing C-branching for therapy and diagnostics
EP0459655A3 (en) Photoresist process employing an i-line peak light source
TW358900B (en) A through screen
ES2187504T3 (es) Vectores no oncovirales, basados en el vmmp, con encapsidacion defectuosa.
DK0638068T3 (da) Fremgangsmåde til fremstilling af (S)-3-amino-1-substitueret-pyrrolidiner
DK0553667T3 (da) Opløselig LDL-receptor, dens fremstilling og anvendelse
ATE187722T1 (de) Cycloaliphatische acryloyl-monomere
FI98987B (fi) Varjoainekoostumus
FI913468A0 (fi) Hiomakivi
ATE181257T1 (de) Testbesteck